cover image: Therapeutic guidelines : Therapeutic guidelines 2009 antiretroviral treatment of adult HIV infection

Premium

20.500.12592/32c2w4

Therapeutic guidelines : Therapeutic guidelines 2009 antiretroviral treatment of adult HIV infection

4 May 2011

Deciding to start ART requires weighing the benefits of treatment on morbidity and mortality against its risks, including toxicity, resistance, drug interactions, and the costs and inconvenience of lifelong treatment. Sustained viral suppression restores and preserves immunologic function, decreasing opportunistic diseases and mortality. The patient must be ready and willing to adhere to lifelong therapy. Advances in ART continue to shift the therapeutic risk-benefit balance to earlier treatment. Improvements in potency, toxicity and tolerability, and pill burden allow for durable viral suppression for most patients.
health hiv aids drugs hiv infections hiv/aids aids antiretroviral agents antiretroviral drugs biology medicine anti-retroviral agents therapy communicable disease clinical medicine hiv infection tenofovir health treatment health sciences medical drugs virus disease diseases and conditions hiv-positive persons antiretroviral treatment (art) darunavir emtricitabine efavirenz abacavir raltegravir julio montaner

Authors

Montaner, Julio

Pages
50
Published in
Canada

Related Topics

All